ALLOVIR INC

Goodwin Life Sciences and Public M&A teams advised AlloVir on its merger with Kalaris Therapeutics, forming a company focused on TH103, an anti-VEGF therapy for retinal diseases. The combined entity, expected to trade as KLRS on Nasdaq, will have ~$100M in cash post-merger, subject to approvals and conditions.

DelveInsight's 'Respiratory Syncytial Virus Pipeline Insight, 2024' report details 50+ companies developing 50+ therapies, including Nirsevimab, Sisunatovir, and RSVpreF, across various stages of clinical trials. Key companies include GSK, Pfizer, and Sanofi, with recent successes like GSK's Arexvy vaccine and MSD's clesrovimab. The report covers mechanism of action, route of administration, and market dynamics.